Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 10/20 | 0.45 |
| ▸ | CA9 | Q16790 | 10/20 | 0.45 |
| ▸ | CA12 | O43570 | 8/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.44 |
| ▸ | CA6 | P23280 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029661 | 0.85 | ENPP3 (0.47) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL14995675 | 0.82 | STAT6 (0.39) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL5117367 | 0.80 | CA2 (0.40) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL4001420 | 0.77 | AURKA (0.59) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL14995680 | 0.77 | CA2 (0.45) | CA2CA1CA9CA12CA14 | |
| SCHEMBL28246733 | 0.75 | CDK1 (0.60) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL3997330 | 0.74 | AURKA (0.58) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL28865417 | 0.72 | CDK1 (0.59) | CA2CDK1KDRCA1CA9 | |
| SCHEMBL1805395 | 0.71 | CA2 (1.00) | CA2CA1CA9CA12CA14 | |
| Ammonia Solution, Strong SCHEMBL5014629 | 0.70 | CDK2 (0.58) | CA2CDK1KDRCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4491/4885CDK1 191/4885KDR 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.